Sankala Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Sankala Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24K	Hold	150	–	–	0.02%	319
2026 Q1	$18.3K	Hold	150	–	–	0.01%	321
2025 Q4	$19.1K	Buy	+150	New	+$17.2K	0.02%	321

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Sankala Group's XBI Position: Q2 2026 in Review

Sankala Group held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 150 shares worth $24K. The position accounts for 0.02% of the portfolio, ranked #319.

Sankala Group first reported a position in XBI in Q4 2025 and has held it in 3 quarters since. 936 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Sankala Group held 150 shares of State Street SPDR S&P Biotech ETF worth $24K as of Q2 2026.
Sankala Group left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.02% of Sankala Group's portfolio in Q2 2026, its #319 holding.
Sankala Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and has held it in 3 quarters since.
936 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Sankala Group's 13F filing for Q2 2026, filed 18 Aug 2026.